Hojo Mariko, Shibuya Tomoyoshi, Nagahara Akihito
Department of Gastroenterology, Juntendo University School of Medicine, Japan.
Intern Med. 2025 Jan 1;64(1):7-15. doi: 10.2169/internalmedicine.2867-23. Epub 2023 Nov 13.
Traditionally, the treatment of chronic constipation has focused on lifestyle modification, dietary guidance and therapy, and osmotic and stimulant laxatives. Recently, several drugs with new mechanisms of action have been introduced as treatments for chronic constipation. In Japan, polyethylene glycol and lactulose can now be administered under insurance coverage. The number of treatment options for constipation has increased dramatically. First, lifestyle modifications and dietary therapies must be implemented. If constipation does not improve sufficiently, specialized functional tests are performed to diagnose physiological subgroups. If functional tests are not available, patients are classified as having the "decreased frequency of defecation" type or the "difficult defecation" type based on the patient's symptoms, with treatment applied according to each type. Medical therapy includes osmotic laxatives, secretagogues, bile acid transporter inhibitors, probiotics, prokinetics, and Kampo medicines. The temporary use of stimulant laxatives, suppositories, enemas, and digital evacuation is also recommended. The usefulness of biofeedback is yet to be determined.
传统上,慢性便秘的治疗重点在于生活方式的改变、饮食指导与治疗以及渗透性和刺激性泻药。最近,几种具有新作用机制的药物已被引入用于治疗慢性便秘。在日本,聚乙二醇和乳果糖现在可以在医保覆盖范围内使用。便秘的治疗选择数量大幅增加。首先,必须实施生活方式的改变和饮食疗法。如果便秘没有充分改善,则进行专门的功能测试以诊断生理亚组。如果没有功能测试,根据患者症状将患者分类为“排便频率降低”型或“排便困难”型,并根据每种类型进行治疗。药物治疗包括渗透性泻药、促分泌剂、胆汁酸转运抑制剂、益生菌、促动力药和汉方药。也建议临时使用刺激性泻药、栓剂、灌肠剂和指压排便法。生物反馈疗法的有效性尚待确定。